Merck Stock News

26 More Cases Of Heart Inflammation Linked To Pfizer Jab Pfizer is already quietly scrambling Friday as the COVID "variant of the moment" raises new questions about the efficacy of its vaccine (while the latest "data" shows Merck may have oversold its mulnupiravir drug as a "miracle cure" for the virus), it appears 26 new cases of the rare side effect known as myocarditis have been reported during the week ending Nov. 21. There is also one new case of blood clots case linked to the AstraZeneca jab following receipt of the first dose. The new case increased the total Thrombosis with thrombocytopenia syndrome (TTS) or blood clots cases to 164 out of 13.4 million doses. Of these 148 (81 confirmed, 62 probable) related to a first dose of and 21 to a second dose (six confirmed, 15 probable). Eight people have died as a result of blood clots six of these were women. Put another way, myocarditis is reported in one to two in every 100,000 people who receive Pfizer. There have also been a total of 150 reports of suspected Guillain-Barre Syndrome (GBS) occurring after vaccination with AstraZeneca, a rare but sometimes serious immune disorder affecting the nerves.

The U.S. FDA is asking advisers if the benefits of Merck''s experimental COVID-19 pill outweigh the risks and if its use should be restricted for some people. The post Merck COVID-19 pill effective but safety questions remain, says FDA appeared first on CityNews Calgary .

The U.S. FDA is asking advisers if the benefits of Merck''s experimental COVID-19 pill outweigh the risks and if its use should be restricted for some people.

Drugmaker says final analysis of trial results showed molnupiravir showed 30 percent risk reduction.

The Food and Drug Administration (FDA) says that while Merck''s experimental COVID-19 antiviral pill is effective, the agency has yet to determine whether the medication can be safely administered during pregnancy.The FDA said a review

FDA scientists consider possible toxicity and birth defects before public meeting next week

American drugmaker Merck has stated that the latest data on its Covid-19 treatment showed the pill to be less effective than initially reported, just days before a panel meeting where US regulators will review the new drug. Read Full Article at RT.com

Cantor Fitzgerald Investment Adviser L.P. boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 177,094 shares of the companys stock after purchasing an additional 259 shares during the quarter. Merck & Co., Inc. makes up 1.0% of Cantor Fitzgerald Investment Adviser L.P.s portfolio, []

BEAM Asset Management LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,971 shares of the companys stock, valued at approximately $223,000. A number of other institutional []

BEAM Asset Management LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,971 shares of the companys stock, valued at approximately $223,000. Other large investors have also recently added to []

New data, in addition to analyses by scientists at the Food and Drug Administration, may take some of the shine off Merck''s experimental Covid pill, molnupiravir.

Merck said its Covid pill showed a 30% reduction in hospitalizations and deaths, based on data from over 1,400 patients

Updated data from the experimental pill for the treatment of COVID-19 by the American company Merck & Co show that its effectiveness is significantly lower than the original report. According to preliminary data from October, "molnupiravir" reduces the risk of death and hospitalization by 50%. Now, in more than 1,400 patients - twice as many as in October - the risk is reduced by 30%. Following the announcement, the company''s shares fell 3%, but this may include the effect on the stock exchanges of the news of the appearance of a mutated version of COVID-19 in South Africa. Preliminary data showed hospitalization of 7.3% of those given the pill twice daily for 5 days and no deaths 29 days after treatment (in the placebo group, 14.1% were hospitalized). The updated data speak of 6.8% hospitalized and one deceased in the treated, as well as 9.7% hospitalized in the control group. /Dnevnik

Merck & Co reported updated data from a late stage study of its experimental Covid-19 drug

U.S. health officials say Merck''s experimental COVID-19 pill is effective but they raised questions about its safety during pregnancy.